DavidASallmanMD

Hematologic Oncology

Assistant Member, Malignant Hematology Department, Moffitt Cancer Center

Overview of Dr. Sallman

Dr. David Sallman is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from University of South Florida Morsani College of Medicine and has been in practice 7 years. He is one of 170 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
12902 Usf Magnolia Dr
# Moffitt
Tampa, FL 33612
Book by Phone+1(929) 600-6590

Fax+1 617-724-7441

Education & Training

University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2013 - 2016
Massachusetts General HospitalResidency, Internal Medicine, 2010 - 2013
University of South Florida College of MedicineClass of 2010

Certifications & Licensure

FL State Medical License 2013 - 2025
MA State Medical License 2012 - 2015
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Junior Faculty Research Award for Clinical Science 2020
Best Abstract Award Winner Moffitt Research Symposium 2016
Alpine Oncology Foundation Young Investigator 2015
Top 3 Award winner for abstract submitted to 8th International Congress on Myeloproliferative Neoplasms, Myelodysplasia and Chronic Myeloid Leukemia 2015
Society for Hematologic Oncology (SOHO) Travel Grant Recipient 2015
ASH Clinical Research Training Institute (CRTI) Participant 2015
ASCO Oncology Trainee Travel Award 2015
Best Abstract Award Winner 2015 Moffitt Research Symposium 2015
Join now to see all

Clinical Trials

Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms Start of enrollment: 2017 May 18
Completed
Phase 1, Phase 2
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 Start of enrollment: 2018 Sep 18
Completed
Phase 1, Phase 2
CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome Start of enrollment: 2018 Dec 14
Active, not recruiting
Phase 1
APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) Start of enrollment: 2019 Jan 11
Completed
Phase 3
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS Start of enrollment: 2019 May 20
Recruiting
Phase 1
Quality of Life Model for Older Patients With AML Start of enrollment: 2020 Jul 08
Active, not recruiting
CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML Start of enrollment: 2021 Jan 14
Active, not recruiting
Phase 1, Phase 2
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA Start of enrollment: 2021 Mar 30
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

5 citations
Myelodysplasia in younger adults: outlier or unique molecular entity?
David A. Sallman, Eric Padron
Haematologica. 2017-06-01
200 citations
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study
Nancy K. Gillis, Markus Ball, Qing Zhang, Zhenjun Ma, YuLong Zhao
The Lancet. Oncology. 2017-01-01
154 citations
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).
Thomas Cluzeau, Marie Sebert, Ramy Rahmé, Stefania Cuzzubbo, Jacqueline Lehmann-Che
Journal of Clinical Oncology. 2021-02-18

Abstracts/Posters

A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti_Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocyti...
David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State
David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts
David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation
David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients _70 Years with Acute M...
David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes
David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia
David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation
David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acu...
David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome
David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing...
David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation
David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (_60 Years Old) with Ac...
David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome
David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies
David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results.
2019 ASCO Annual Meeting - 6/1/2019
Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
SNP-Array Genome Wide Association Study Meta-Analysis Identifies Innate Immune Susceptibility Loci Associated with Non-Del(5q) Myelodysplastic Syndromes Predisposition
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

Addressing Frequency of Care to Improve Quality of Life in Patients with Low-Risk AnemiaJuly 25th, 2024
Magrolimab plus Azacitidine Results in Promising Activity in Higher-Risk MDS PatientsMarch 9th, 2023
First-in-Class Investigational SX-682 Demonstrates Single-Agent Efficacy in Patients with Hypomethylating Agent Failure Myelodysplastic SyndromesDecember 9th, 2022
Join now to see all